# BPC-157 TB-500 FAQ: The Wolverine Blend, Answered From the Record > BPC-157 TB-500 questions answered from the literature: what the Wolverine blend is, why the two peptides are paired, whether synergy is proven, the FDA 503A status, safety signals, and dose-context facts. Every answer maps to a cited study or the FDA record — the definitional, the mechanistic, the dose-context, the safety, and the regulatory questions about the Wolverine blend. ## What the blend is BPC-157 TB-500 questions cluster around one ambiguity: the blend is marketed as a single thing but studied as two. The answers below separate the per-component evidence from the blend-level claims, and cite the source for every quantitative point. ### What is the BPC-157 and TB-500 blend used for in research? In animal-model research the two peptides are studied separately for tissue repair: BPC-157 in tendon, ligament, muscle, and wound models [1], [5], [6], and TB-500 / Thymosin Beta-4 in actin-driven cell migration, wound, and angiogenesis models [4], [7]. The blend itself has no controlled-study indication. ### What is the Wolverine peptide blend? Wolverine is a research-community name for a two-peptide pairing of BPC-157 (a 15-amino-acid pentadecapeptide) and TB-500 (the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4) [9]. It is not a single chemical entity or an approved product. ### What is BPC-157 and TB-500? BPC-157 is a synthetic stable fragment of a human gastric-juice protein studied as a cytoprotective and angiogenic signal; TB-500 is the synthetic actin-binding heptapeptide (residues 17-23) of Thymosin Beta-4 [3]. The blend co-formulates the two. ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale pairs BPC-157's angiogenic-cytoprotective signal (VEGFR2-Akt-eNOS) [2] with TB-500's cytoskeletal actin-sequestration signal as complementary, largely non-overlapping mechanisms [4]. The "synergy" is a theoretical extrapolation, not a finding from a controlled combination study. ## Mechanism and difference ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it — Thymosin Beta-4 caps both ends of the monomer — regulating the cytoskeletal dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3], [4]. ### How does BPC-157 work compared to TB-500? BPC-157 supplies a local cytoprotective and pro-angiogenic signal — VEGFR2 up-regulation, Akt-eNOS, growth-hormone-receptor sensitization of fibroblasts [2], [5]; TB-500 supplies an intracellular actin-sequestration signal [3]. They act through complementary, largely separate pathways. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid gastric-juice-derived pentadecapeptide acting on angiogenesis and cytoprotection [1]; TB-500 is a 7-amino-acid Ac-LKKTETQ fragment of Thymosin Beta-4 acting on actin and cell migration [3]. Different size, origin, and proposed mechanism. ### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? Both promote angiogenesis by distinct routes: BPC-157 via VEGFR2 up-regulation and the VEGFR2-Akt-eNOS pathway [2], and Thymosin Beta-4 via endothelial-migration angiogenesis [4]. Findings are from cell and animal models. ### Does the BPC-157 TB-500 blend help wound healing? Thymosin Beta-4 promotes re-epithelialization, reduces myofibroblast number (limiting scar), and is angiogenic in animal wound models [4], and BPC-157 has broad cytoprotective wound activity [2]; combined wound-healing efficacy in humans has not been studied. ## Efficacy, evidence, and timeline ### Does the BPC-157 TB-500 blend help tendon and ligament injuries? BPC-157 accelerated healing of a transected rat Achilles tendon [1] and improved transected-tissue fibroblast outgrowth [5]; Thymosin Beta-4 enhanced rat MCL healing [8]. All findings are in animal models; no human tendon or ligament trial of the blend exists. ### Does BPC-157 and TB-500 help muscle tears and recovery? BPC-157 accelerated functional recovery of crushed rat gastrocnemius muscle [6], and injury-induced Thymosin Beta-4 acted as a myoblast chemoattractant [7]. These are rodent findings; combined human efficacy is unproven. ### How long does it take BPC-157 and TB-500 to work for an injury? Animal studies report tissue-level repair markers over days to weeks (transected-tendon [1], muscle-crush [6] models), but no validated human timeline exists for either peptide or the blend. ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. A 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only one human — makes no mention of TB-500 or combination use [10]; no peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together. ### Are there human clinical trials on the BPC-157 + TB-500 combination? No. Human data exist only for the individual constituents and are thin — three small BPC-157 pilots; full-length Thymosin Beta-4 Phase 1 studies, not the TB-500 7-mer. The combination's human efficacy and safety are unproven [12], [11]. ## Dose-context and safety ### What is the half-life of BPC-157 and TB-500? BPC-157 elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study. No validated human half-life exists for the TB-500 heptapeptide or the blend; human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics [4]. ### How do you cycle BPC-157 and TB-500? No validated cycle exists for the blend. Community "loading then maintenance" protocols and fixed-ratio vials have no controlled-trial basis [10]; the published evidence is per-component and from animal models. ### How much BPC-157 and TB-500 should be used per week? There is no validated weekly dose for the blend. Rodent BPC-157 doses are commonly expressed per body weight (around 10 µg/kg) [1] and Thymosin Beta-4 doses span a wide range [4]; these are species-specific research figures, not human guidance. ### How often should you inject BPC-157 and TB-500? No validated injection frequency exists for the blend. The underlying rodent studies used various schedules (Thymosin Beta-4 twice weekly intraperitoneally in one six-month model) [4]; these are research designs, not human dosing instructions. ### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [9]. ### What are the side effects of BPC-157 and TB-500? Human safety data for the blend are absent. A 2026 Sports Medicine review of unapproved musculoskeletal peptides, listing both compounds, notes scarce human safety data and potential for serious harm [11]; combining two unapproved peptides doubles that uncertainty. ### Does TB-500 cause cancer or promote tumor growth? Thymosin Beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a safety consideration, not a demonstrated effect of the blend. ## Regulation and access ### Are BPC-157 and TB-500 FDA approved or banned by WADA? Neither is FDA-approved for human use; both are in FDA's 503A Category 2 as of the September 29, 2023 update [16], and both are WADA-prohibited. The [WADA and FDA status](/legal-status#wada) is covered in full on the legal-status page. ### Is Wolverine legal? Neither component of the Wolverine blend is an FDA-approved drug, and the blend has no approved indication. Both BPC-157 and TB-500 are in FDA's 503A Category 2 (effective September 29, 2023) — FDA identified them as bulk substances that may present significant safety risks, so they are not within its compounding enforcement-discretion policy [16], [15]. This is general regulatory information, not legal advice. ### Can you get BPC-157 from a compounding pharmacy? BPC-157 is currently in 503A Category 2, the category FDA identified as raising significant safety risks and not covered by its enforcement-discretion policy [16]. A compounder may use a bulk ingredient only if it is eligible under the 503A/503B rules, so a Category 2 placement means routine 503A access is restricted while that status stands [15]. BPC-157 is also on the July 23-24, 2026 PCAC agenda as a candidate under evaluation [14]. ### What is the FDA 503A status of Wolverine? Neither component is FDA-approved. Both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" are in 503A Category 2, effective with FDA's September 29, 2023 update [16]. Both are on the published agenda of the July 23-24, 2026 PCAC meeting as substances being considered for the 503A Bulks List — a scheduled discussion, not a decision [14]. The blend has no approved therapeutic indication. --- Two repair signals tracked as two bands of cold light — BPC-157's green leg and TB-500's violet leg, each read against its own studies, the convergence left labeled theoretical and the FDA 503A status read first; no clinic behind the aurora and nothing here dispensed.